tapebrief
AFL · Q4 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

AFL · Q1 2026 Earnings

Aflac

Reported April 29, 2026

30-second summary

30-second take: Aflac printed Q1 adjusted EPS of $1.75 on $4.35B in total revenue — though the +27.9% YoY headline is a non-economic optical effect from the prior-year period's $924M adjusted net investment loss reversing to a $103M gain; net earned premiums actually declined 2.1% YoY ($3.31B vs. $3.38B), the cleaner read on the operational top line. Adjusted ROE came in at 12.8% and GAAP ROE at 13.7%. The substantive disclosures are qualitative: management reaffirmed the FY2026 Japan benefit ratio band at 60–63% — passing its first test under the revised framework — but introduced explicit Q2 caution, guiding the Corporate and other segment to "slightly negative in terms of pre-tax earnings," and Yoshizumi characterized Japan cancer insurance (Morito) 2026 sales as expected to be "equivalent to that of 2025." The mix is the cleanest possible read on management's posture: framework intact, near-term softness telegraphed, full-year confidence preserved without raising it.

Headline numbers

EPS

Q1 FY2026

$1.75

Revenue

Q1 FY2026

$4.35B

+27.9% YoY

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$4.35B+27.9%$4.87B-10.7%
EPS$1.75—$1.57+11.5%

Guidance

Aflac reaffirmed full-year Japan benefit ratio guidance; qualitatively guided Q2 FY2026 to be slightly negative in pre-tax earnings for a segment.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Reaffirmed unchanged this quarter: Aflac Japan benefit ratio (60% to 63%)

Segment performance

Q1 FY2026
SegmentQ1 FY2026YoY
Aflac Japan$0.759B+5.1%
Aflac U.S.$0.363B+1.4%
Pretax Adjusted Earnings - Aflac Japan¥119,117 million—
Pretax Adjusted Earnings - Aflac U.S.$363 million—

Capital & returns

Q1 FY2026
SegmentQ1 FY2026
Book Value Per Share58.69

Other KPIs

Q1 FY2026
SegmentQ1 FY2026
Adjusted Earnings Per Share (diluted)1.75
Return on Equity (U.S. GAAP)13.7%
Adjusted Return on Equity12.8%
Aflac U.S. Premium Persistency79.3%
Aflac U.S. New Annualized Premium Sales$318 million

Management tone

Narrative arc: Q3'25 multi-product offensive → Q4'25 margin reset with inflection pushed out → Q1'26 framework holds but near-term caution surfaces.

Last quarter the story was a margin reset pushing the inflection past 2026; this quarter management revealed the structural math underneath the inflection delay. From the call: "in order to get back to Earned Premium growth…that's the kind of sales level that you basically need to get to in order to achieve zero or flat in force period over period on an annual basis." The ~¥90B figure is the annual new-sales level required to offset lapsation and hold in-force flat — not a cyclical drag but the gating constraint, and management is now telling the market that just stopping the bleeding requires ¥90B in annual new sales. This is the most candid disclosure of the Japan structural math we've seen in recent coverage.

External reinsurance has been quietly upgraded from sideline to capital-light growth pillar. Max this quarter: "over time, we certainly expect that this would be material to the company." Same call: "will consume capital" but "not…alter our capital deployment back to shareholders." The signal is that reinsurance is being positioned as a parallel growth track that does not crowd out the buyback program — a meaningful posture shift for a company whose capital story has been almost entirely about return-of-capital pacing.

The US core agent channel framing has hardened from "stable contributor" to candidly "slightly down to flat." Virgil this quarter: "that particular business, we've got some investments we're doing right now to try to get growth out of that business. But what you're seeing right now, it's slightly down to flat." This is the explicit acknowledgment that the headline +1.4% US pretax growth is being held up by the group/LAD mix while the traditional voluntary agent block is contracting. The Q3'25 framing of US mix-shift as a strategic tailwind has matured into Q1'26 framing where the legacy block is now openly described as a drag requiring investment to stabilize.

The reserve re-measurement disclosure pattern continues to flag underlying-vs-reported divergence. This quarter Max called out 70bps Japan above plan, and 230bps US total re-measurement impact with 80bps above plan. Stripped of those, US benefit ratio sat at the low end of the 48–52% band rather than the middle. Management is being deliberate about not letting re-measurement gains anchor expectations: the underlying basis is what matters, and that is precisely at the bottom of the guided band, not below it.

The explicit "slightly negative" Q2 segment pre-tax earnings call is unusual for Aflac's typical disclosure cadence. Combined with reaffirmed FY2026 confidence, it implies a sharp back-half recovery — a shape management has not previously asked the market to underwrite at this granularity. The risk is that if Q2 prints worse than "slightly negative," the FY band has to flex; if it prints better, management has built a low bar.

Recurring themes management leaned on this quarter:

Japan sales momentum driven by new product launches (Anshin Pallet, Morito cancer, Sumitatsu) amid persistent lapsation headwindsU.S. group business outperformance (25% growth in group categories) offsetting flat-to-declining agent/core voluntary businessEarned premium growth in Japan structurally challenged by ~90bn yen annual lapsation requiring equivalent new sales just to break evenExternal reinsurance strategy positioning as long-term but capital-light growth opportunity in Japan marketStrong capital and liquidity position enabling $1.3bn shareholder returns in Q1 while maintaining ESR 227-243%Reserve re-measurement gains (70bp Japan, 230bp U.S.) exceeding plan expectations creating near-term earnings tailwinds

Risks management surfaced:

Lapse and reissue activity on cancer insurance products shifting to younger/shorter-duration policies with IRR implicationsCommercial real estate portfolio valuations remain 'depressed' despite management belief in 'true intrinsic value'Japan yen interest rate increases creating 'slightly negative impact to ESR because of increased capital charges associated with mass lapse risk'U.S. agent recruitment and retention challenges in competitive labor market; core agent business 'slightly down to flat'Currency volatility: yen/dollar leverage ratio exposed to 'significant yen strengthening scenario' despite 65% of debt in yen

Answers to last quarter's watch list

Japan benefit ratio actual landing inside 60–63% — Reaffirmed and the framework held on its second test. Management disclosed a Q1 total Japan benefit ratio of 62.9%, with a 70bps re-measurement benefit above plan, implying the underlying ratio is tracking in-band. The credibility damage from the Q4 revision has not been compounded this quarter. Status: Resolved positively
Japan underlying earned premium trend vs. -1% to -2% guide — Underlying earned premiums declined 1.3% in the quarter, squarely within the guided band. Management now anchors the ~¥90B annual new-sales requirement as the threshold to offset lapsation and achieve flat in-force, and characterizes current underlying earned premium as running "in this range of negative 1% to 2%." Status: Continue monitoring
US net earned premium growth crossing into mid-3% range — US net earned premiums grew 3.5% in the quarter, brushing the lower bound of the guided 3–6% range. The candid framing of the core voluntary block as "slightly down to flat" suggests the mid-3% pace is being carried by the group mix rather than the legacy book. Status: Continue monitoring
US group/LAD isolated growth holding double-digit — Resolved favorably. Per Virgil this quarter, the filed group category (dental/vision + core VB + group life/absence/disability) grew +12.4%, while the narrower "buy the bills" grouping (dental/vision + group LAD + consumer markets) grew +25%, and the dental/vision property alone was up +52%. Both cuts validate the mix-shift thesis as the load-bearing US growth driver. Status: Resolved positively
Buyback pacing — Q1 buybacks were $1.0B and dividends $315M (aggregate $1.3B in shareholder returns). Max characterized capital deployment as continuing along the lines pursued "over the last couple of years," with reinsurance not expected to alter return of capital. Status: Resolved positively
USP-to-ESR benefit trajectory — Management flagged that yen interest rate increases are creating a "slightly negative impact to ESR because of increased capital charges associated with mass lapse risk." ESR landed at 227% regulatory / 243% with USP (16pts USP benefit). The sensitivity is real but contained. Status: Continue monitoring

What to watch into next quarter

Q2 segment pre-tax earnings landing within "slightly negative": management has explicitly guided to a negative print. Watch whether the Q2 disclosure lands at low-single-digit decline or steps to mid/high-single-digit, which would force a FY band flex.

Japan benefit ratio Q2 actual underlying basis at or below 61.5% (band midpoint): with 70bps Q1 above-plan re-measurement favorability stripped, the underlying ratio anchor is the cleanest test of the 60–63% framework on its third test.

External reinsurance disclosure cadence and capital consumption: Max has positioned this as "material over time." Watch whether Q2 or Q3 discloses a sized transaction or remains at the qualitative level — the divergence determines whether this is a real lever or rhetorical.

Japan H1 sales pace vs. analyst-derived ~¥45B half-year run-rate (roughly half of management's ¥90B annual offset threshold): tracking H1 Japan new annualized premium sales against this analyst-implied pace is the cleanest read on whether the inflection date is being pulled forward or pushed further out from 2027+.

US "buy the bills" sustaining +20% or above: the narrow +25% Q1 print is the only meaningfully accelerating US growth grouping. A step-down to mid-teens in Q2 would suggest the Q1 print was lumpy.

Buyback pace vs. the $1.0B Q1 baseline: confirming whether the Q1 buyback level is sustained into Q2 given management's framing that reinsurance will not alter capital return.

Q2 yen rate moves and ESR capital charge sensitivity: management has flagged that rising yen rates compress ESR via mass lapse capital charges. Watch the Q2 ESR print vs. the 227% regulatory / 243%-with-USP Q1 baseline.

Sources

  1. Aflac Q1 2026 Financial Supplement (SEC): https://www.sec.gov/Archives/edgar/data/4977/000162828026028396/afl033126-fabdocument.htm
  2. Aflac Q1 2026 earnings commentary (Dan Amos, Max Brodén, Virgil Miller, Koide).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.